People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ascend Advanced Therapies Group, Inc. | — | Other | Series D+ | $130.6M | $1.2B | 2024 |
| Ascend Gene & Cell Therapies Ltd. | — | Other | Series C | $66.6M | $680.5M | 2023 |
Michael Beecham at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Beecham on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 2 | 12 |
| Andrew Sinclair | 2 | 5 |
| Balaji Muralidhar | 2 | 3 |
| Timothy Funnell | 2 | 2 |
| Eric Shiozaki | 1 | 4 |
| William Hawkins | 1 | 2 |
| Andrew May | 1 | 2 |
| Justin Kern | 1 | 2 |
| Wesley McConnell | 1 | 1 |
| Evis Hursever | 1 | 1 |
| Michael Stella | 1 | 1 |
| Andrew Kozlov | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.